Fiscal Year Ended March 31, 2026
Overview of Financial Results (Core basis)
(Millions of yen)
| Fiscal year ended March 31, 2025 |
Fiscal year ended March 31, 2026 |
Change | Change (%) | |
|---|---|---|---|---|
| Revenue | 486,871 | 515,785 | 28,914 | 5.9％ |
| Core operating profit | 112,667 | 137,135 | 24,468 | 21.7％ |
| Core profit for the year (attributable to owners of the Company) |
90,361 | 103,499 | 13,139 | 14.5％ |
Revenue
Revenue totaled ¥515.8 billion, which was an increase of ¥28.9 billion (5.9%) from the previous fiscal year (year on year).
Sales of Domestic Products
- Sales of domestic products totaled ¥281.4 billion, which was a decrease of ¥10.3 billion (3.5%) year on year.
- Sales of Opdivo Intravenous Infusion for malignant tumors decreased by ¥6.0 billion (5.0%) year on year to ¥114.3 billion, mainly due to the intensified competitive environment. Sales of Forxiga Tablets for diabetes, chronic heart failure and chronic kidney disease decreased by ¥1.4 billion (1.5%) year on year to ¥88.2 billion, mainly due to the entry of generic products in December 2025.
- With respect to other main products, sales of Orencia Subcutaneous Injection for rheumatoid arthritis were ¥26.6 billion (0.0% decrease year on year). Sales of Glactiv Tablets for type-2 diabetes were ¥13.2 billion (27.9% decrease year on year). Sales of Velexbru Tablets for malignant tumors were ¥11.9 billion (12.8% increase year on year). Sales of Ongentys Tablets for Parkinson’s disease were ¥9.0 billion (17.3% increase year on year). Sales of Parsabiv Intravenous Injection for Dialysis for secondary hyperparathyroidism on hemodialysis were ¥9.0 billion (6.6% increase year on year). Sales of Kyprolis for Intravenous Infusion for multiple myeloma were ¥7.5 billion (12.9% decrease year on year). Sales of Braftovi Capsules for malignant tumors were ¥5.6 billion (33.8% increase year on year).
Sales of Overseas Products
- Sales of overseas products totaled ¥61.2 billion, which was an increase of ¥22.1 billion (56.5%) year on year.
- Sales of QINLOCK® (ripretinib) for gastrointestinal stromal tumor, marketed by Deciphera Pharmaceuticals, LLC, the operating company of Deciphera Pharmaceuticals, Inc., increased by ¥12.9 billion (50.6%) year on year (the previous period included only nine months of sales from July to March) to ¥38.4 billion. Additionally, sales of ROMVIMZA® (vimseltinib), also marketed by Deciphera, for tenosynovial giant cell tumor (TGCT) treatment, were ¥8.3 billion.
Royalty and Others
- Royalty and others increased by ¥17.1 billion (10.9%) year on year to ¥173.2 billion, mainly due to an increase in royalty revenue from Bristol-Myers Squibb Company.
[Core Operating Profit]
Core operating profit was ¥137.1 billion, an increase of ¥24.5 billion (21.7%) year on year.
- Cost of sales was ¥107.0 billion, roughly unchanged from the corresponding period of the previous fiscal year.
- Research and development costs increased by ¥1.8 billion (1.2%) year on year to ¥145.1 billion mainly due to the inclusion of research and development expenses from Deciphera Pharmaceuticals, LLC (the previous period accounted for only nine months of Deciphera’s expenses (July to March), whereas the current period includes twelve months (April to March)), despite a decrease in research costs.
- Selling, general, and administrative expenses (except for research and development costs) increased by ¥1.4 billion (1.1%) year on year to ¥123.6 billion mainly due to the inclusion of business operating costs from Deciphera Pharmaceuticals, LLC (the previous period accounted for only nine months of Deciphera’s expenses (July to March), whereas the current period includes twelve months (April to March)), despite ongoing efforts to improve cost efficiency.
[Core profit for the year] (attributable to owners of the Company)
Core profit attributable to owners of the Company increased by ¥13.1 billion (14.5%) year on year to ¥103.5 billion.
Overview of Financial Results (IFRS (Full) basis)
The consolidated results for the current fiscal year on a full basis are shown in the table below.
(Millions of yen)
| Fiscal year ended March 31, 2025 |
Fiscal year ended March 31, 2026 |
Change | Change (%) | |
|---|---|---|---|---|
| Revenue | 486,871 | 515,785 | 28,914 | 5.9％ |
| Operating profit | 59,747 | 92,236 | 32,489 | 54.4％ |
| Profit before tax | 59,328 | 92,654 | 33,326 | 56.2％ |
| Profit for the year (attributable to owners of the Company) |
50,047 | 69,767 | 19,720 | 39.4％ |
Operating profit, profit before tax, and profit for the year attributable to owners of the parent all increased compared with the previous fiscal year.
Performance on a full basis includes items that are excluded from a core basis, such as amortization of intangible assets, impairment losses, and cost of inventories measured at fair value.
In the current fiscal year, amortization of intangible assets amounted to ¥25.6 billion (previous fiscal year: ¥14.6 billion), and impairment losses were ¥2.1 billion (previous fiscal year: ¥8.0 billion), and cost of inventories measured at fair value amounted to ¥9.1 billion (previous fiscal year: ¥12.9 billion).
Cost of sales in the previous fiscal year included a sales milestone payment of ¥13.6 billion related to Forxiga Tablets, which were sold under the co-promotion agreement with AstraZeneca.
Other expenses in the current fiscal year include the following major items:
- A loss of ¥4.3 billion representing the difference between the consideration received for the transfer of selling rights following the termination of the co-promotion agreement with AstraZeneca and the decrease in the carrying amount of the selling rights for Forxiga Tablets.
- A loss of ¥1.7 billion associated with revisions to the retirement benefit plan following the transition to a defined contribution pension plan
- A loss of ¥1.4 billion associated with product recall related to certain products